Aims Cardiac involvement is the main determinant of poor outcomes in sarcoidosis. Right ventricular (RV) dysfunction and left ventricular (LV) late gadolinium enhancement (LGE) have been reported to be predictive of adverse outcome in non-ischaemic cardiomyopathies. The aim of our study was to determine whether delayed RV LGE with cardiovascular magnetic resonance would be predictive of adverse events in addition to LV LGE during the long-term follow-up of pulmonary sarcoidosis patients. Methods and results Eighty-four consecutive biopsy-proven pulmonary sarcoidosis patients were followed for a median of 56 months after baseline delayed contrast-enhanced cardiac magnetic resonance. The composite primary endpoint consisted of admission for congestive heart failure, sustained ventricular tachycardia, appropriate implantable cardioverter defibrillator therapy, pacemaker implantation for high degree atrio-ventricular block, or cardiac death. The composite secondary endpoint included all-cause mortality in addition to the primary endpoint. RV and LV LGE were demonstrated in respectively 12 and 27 patients. Five of 10 events included in the primary endpoint occurred in the group with RV LGE. RV LGE, LV, or biventricular LGE yielded Cox hazard ratios of 8.71 [95% confidence interval (CI) 1.90-23.81], 9.22 (95% CI 1.96-43.45), and 12.09 (95% CI 3.43-42.68) for the composite primary endpoint. In a multivariate model, the predictive value of biventricular LGE for the composite primary and secondary endpoints was strongest. Kaplan-Meier event-free survival curves were most significant for RV LGE and biventricular LGE (log rank with P < 0.001).
Introduction
Sarcoidosis is a rare inflammatory condition of unknown aetiology, which results in granulomatous infiltration and focal myocardial scar in approximately a third of patients. Major cardiac morbidity or mortality has been reported in approximately 5-10% of sarcoidosis patients. 1 Diagnosing cardiac sarcoidosis (CS) can be challenging, and several noninvasive diagnostic imaging modalities have been used over the years. Recently, delayed contrast-enhanced cardiac magnetic resonance (DECMR) and positron electron tomography (PET) showed most diagnostic and prognostic promise. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] DECMR has become the gold standard test for detecting and quantifying focal myocardial scar, a predictor of high degree atrio-ventricular block (AVB), heart failure [congestive cardiac failure (CCF)], ventricular tachycardia (VT), and sudden cardiac death (SCD) in CS. [2] [3] [4] [5] [6] [7] [8] [10] [11] [12] [13] [14] [15] (Table 1A and 1B) Systolic right ventricular (RV) impairment and multi-focal RV We previously demonstrated the diagnostic accuracy of DECMR for CS and reported on RV involvement in pulmonary sarcoidosis utilizing CMR. 19, 20 We currently report on the prognostic value of RV LGE in addition to left ventricular (LV) LGE in patients suffering from pulmonary sarcoidosis.
Methods

Patient population
Between July 2001 and August 2010, we prospectively followed 84 consecutive patients with histologically proven pulmonary sarcoidosis. These patients had been referred for cardiac evaluation, either because of cardiac symptoms (palpitations, congestive heart failure, (pre)syncope, and chest discomfort) or for routine cardiac assessment ( Figure 1 ). Patients were excluded in case of standard contraindications to DECMR. Approval for our project was obtained from the local Institutional Review Board.
Cardiovascular magnetic resonance protocol
The CMR studies were performed using a commercial 1.5 T magnetic resonance scanner with a cardiac-dedicated, phased-array coil. The CMR studies were electrocardiogram (ECG) triggered by standard software. Studies consisted of multi-phase, multi-slice, steady-state free precession and fat-saturated T2-weighted spin echo (64 patients) breathhold sequences of the short-axis, vertical long-axis, and horizontal long-axis views. The short-axis images covered the LV and RV from base to apex. The steady-state free precession sequences (typical repetition time: 3.5 ms; echo-time 1.4 ms; flip-angle 55°, temporal resolution 50 ms, voxel size 1.6 × 1.6 × 10 mm, no gap) were performed to assess regional wall-motion abnormalities, ventricular volumes, masses, and ejection fractions [left ventricular ejection fraction (LVEF) and right ventricular ejection fraction (RVEF)]. T2-weighted studies were performed to assess for the presence of myocardial inflammation. Contrast-enhanced and T2-weighted images were obtained in diastole to minimize artefact due to cardiac motion. Ten minutes after the additional administration of 0.1 mmol/kg gadolinium-diethylenetriaminepentaacetic acid (Schering, Berlin, Germany), a two-dimensional segmented inversion recovery-gradient echo breath-hold sequence (short axis, vertical long axis, and horizontal long axis, voxel size 1.6 × 1.6 × 10 mm, without gap), was used to assess for LGE. The inversion time (250 to 400 ms) was determined on an individual basis to obtain optimal nulling of the unenhanced myocardial signal.
Cardiovascular magnetic resonance analysis
The CMR studies were analysed offline by two experienced blinded observers who independently evaluated the study findings using commercially available software (CAAS MRV 3.4, Pie Medical Imaging, Maastricht, the Netherlands). Endocardial and epicardial contours were manually delineated in end-diastolic and end-systolic short-axis slices to determine LV and RV end-diastolic volumes (LVEDV and RVEDV), end-systolic volume, LVEF, RVEF, and LV and RV end-diastolic masses, which were indexed to body surface area. The presence and distribution of LGE and increased T2 signal were determined by consensus, and LV LGE was localized according to the 17-segment model. LGE was considered present only if confirmed on both short-axis and matching long-axis myocardial locations.
LGE was quantified by a semi-automatic detection method using the signal intensity threshold of ≥2 SD above a remote reference region. The distribution of LGE was characterized as subendocardial, mid wall, sub-epicardial, patchy, or confluent transmural. When more than one pattern was present, the distribution was characterized on the basis of the predominant pattern. There was excellent intraobserver and interobserver correlation for ventricular volumes, masses, and ejection fractions. Interobserver agreement when determining the presence/localization of LGE was good (kappa 0.85, P < 0.001). The intra-class correlation coefficient for LV LGE was 0.989 [0.981-0.993] (P = 0.001).
Clinical follow-up
Scheduling of follow-up visits was 4-6 monthly and left at the discretion of the managing clinician. Resting 12-lead surface ECGs and 24-72 h ambulatory ECGs were performed and evaluated for intermittent intra-ventricular or atrioventricular conduction disease and/or ventricular arrhythmias. Sustained VT (sVT) was defined as VT with a rate >100 beats/min, lasting for at least 30 s. Implanted cardioverter defibrillators (ICD) or pacemakers (PM) were interrogated every 4 months and assessed for ventricular arrhythmias. At regular intervals and at the end of our study, outcome data were collected from the family physician and managing specialist.
Variables, definitions, adverse events, and composite endpoints
The composite primary endpoint consisted of newly developed AVB resulting in PM implantation, admission for CCF,
sVT, appropriate ICD therapy for sVT or ventricular fibrillation (VF), or cardiac death. Appropriate ICD therapy was defined as anti-tachycardia pacing (ATP) or shock for fast VT (R-R <320 ms) or VF. The composite secondary endpoint included all-cause death in addition to the primary endpoint. Peak systolic RV pressures over 40 mmHg were considered LGE, late gadolinium enhancement; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; PES, programmed electrical stimulation; PM, pacemaker; RV, right ventricle; RVEF, right ventricular ejection fraction; SCD, sudden cardiac death; sVT, sustained ventricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia.
Right ventricular scar predicts outcome in sarcoidosis 161 to represent pulmonary hypertension. RV end-diastolic wall thickness over 5 mm was considered evidence of RV hypertrophy. RV dysfunction was defined as an RVEF <45% by CMR. 21 
Statistical analysis
All statistical analyses were performed using statistical software (Version 21.0, SPSS; Chicago, IL). Continuous normally distributed data were expressed as mean ± SD, and between-group comparisons were made using the parametric t-test for independent samples or Mann-Whitney U test when appropriate. In non-normally distributed continuous data, the median and interquartile ranges were determined, and between-group comparisons were made with the Wilcoxon test. Categorical variables were assessed using the χ 2 or Fisher's exact test when appropriate. Linear regression analysis was used to determine the relationship between LGE, LVEDV, and LVEF. Univariate analyses of the risk for adverse outcome associated with selected variables were performed with the Cox proportional hazards model. A P value of <0.05 was considered statistically significant. The hazard ratio (HR) for the prediction of events was calculated for each of the outcomes using a multivariable Cox regression model; two-tailed values of P < 0.05 were considered significant. Composite event curves were determined according to the Kaplan-Meier method, and comparisons of cumulative event rates were performed using the log-rank test. Receiver operating characteristic (ROC) curves were used to examine the performance characteristic of %LGE mass. Area under the curve, and 95% confidence of the ROC curve, was calculated to provide a measure of the accuracy of %LGE mass to predict combined adverse outcomes. Figure 1 and Table 2 demonstrate the baseline characteristics of the included 84 patients. Twenty-nine patients had CS according to the Heart Rhythm Society (HRS) criteria, 18 according to the Japanese Ministry of Health and Welfare criteria. Twenty-five (30%) patients presented with cardiac symptoms (palpitations, (pre)syncope, chest discomfort, and congestive heart failure), while the remaining 59 patients (70%) experienced non-specific symptoms (fatigue) or were routinely screened for CS. According to the American College of Cardiology/American Heart Association/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities, an ICD or PM were implanted in respectively 14 (four ICD/biventricular PM) and two patients after the baseline DECMR study. 23 Heart failure was managed according to current optimal practice.
Results
Patient characteristics
Cardiovascular magnetic resonance findings
The findings with DECMR are displayed in Table 3 . Twelve patients (44%) had RV LGE, predominantly involving the right-sided interventricular septum and/or ventricular insertion points. Two patients had isolated RV LGE. Patients with RV LGE had significantly more %LV LGE than those without RV involvement [32% (23-41) vs. 10% (2-18), P = 0.006], and RV LGE correlated with the presence of pulmonary hypertension (P = 0.022), RV hypertrophy (P = 0.050), and impaired RV function (P < 0.001).
The LGE involved 4-39% of LV mass, and predominantly involved the interventricular septum, and basal LV segments.
LGE was equally distributed over the three myocardial layers and was patchy (56%) or confluent transmural (44%). In 16 patients (59%), three myocardial layers were involved. In 12% of patients (7/59) who were routinely evaluated, asymptomatic myocardial scar was present, though significantly smaller when compared with the symptomatic group [8% (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) vs. 28% (8-39), P = 0.001).
LGE strongly correlated with the presence of cardiac symptoms, ECG abnormalities, VT, LVEDV, and LVEF (P < 0.001). The transmural extent of LGE correlated with segmental wall-motion abnormalities (P < 0.001). Linear regression analysis demonstrated a decrease in LVEF of 7.27% for every 10% increase in LGE (r 2 0.392, P value < 0.001, 95% CI, À5.25% to À9.30%). For every 10% increase in LGE, the LVEDV increased 9.1 mL in volume (r 2 0.239, P < 0.001, 95% CI 5.27-12.92 mL). In patients with sVT at presentation, the median LVEF was significantly poorer, and LV mass, LVEDV index, and %LV LGE are significantly higher when compared with those without sVT at presentation [respectively 60% (53-67) vs. 51% (34-68) (P = 0.001), 55 (44-66) vs. 73 mL (50-95) (P = 0.011), 111 (80-142) vs. 145 g (95-195) (P =0.028), and 14% (range 2-38) vs. 33% (22-55) (P = 0.016)].
Follow-up results
Figures 1A and 1B and illustrate the baseline findings and outcomes. During a median follow-up of 56 months (1-90 months), eight patients (30%) with LGE experienced an adverse event. All adverse cardiac events occurred in patients who had presented with cardiac symptoms. A 57-year-old woman (New York Heart Association class 3, non-dilated, scarred LV, LV LGE 32%, and non-sustained VTs at rest) awaiting elective ICD implantation experienced SCD, one patient was admitted because of CCF, and six patients had appropriate ICD therapy/discharge for sVT/VF. 
Right ventricular scar predicts outcome in sarcoidosis
The average annualized ICD therapy rate was 11.1%. Three layer confluent transmural LGE predicted arrhythmic events (P = 0.018) and the composite primary endpoint (P = 0.003). VT at inclusion or during follow-up did not correlate with any specific localization grouping of LGE, such as basal septal LGE. Two patients, one presenting with palpitations and the other with pre-syncopal symptoms, both without LGE (2/57, 4%) or T2 signal, suffered an adverse event, respectively sVT after 10 months and PM implantation for third degree AVB after 6 months. Endpoints occurred up to 80 months after baseline CMR. Three patients died of non-cardiac conditions, respectively sepsis, respiratory failure due to extensive pulmonary fibrosis, and malignancy.
None of the patients with non-specific symptoms, such as fatigue, who had been routinely evaluated for cardiac involvement and had LGE [7/59 (12%), LV LGE 5.9 ± 3.8%] developed adverse cardiac events during follow-up. (Figure 2 ). In the present patient population, ROC curve analysis indicated that %LV LGE had the modest ability to predict the composite primary adverse outcome (area under the curve = 0.77, 95% CI 0.58-0.95). A cut-off level of 7% LV LGE best predicted combined adverse cardiac outcomes, with a sensitivity of 70% and a specificity of 85%. The test's positive and negative predictive values were 39% and 95%, respectively. Figures 3-6 demonstrate LGE in symptomatic patients with and without adverse events during follow-up.
Predictors of events
One appropriate shock would be delivered for every 2.5 implanted ICDs in sarcoidosis patients, when based on the combination of cardiac symptoms, abnormal ECG and/or rhythm monitoring, and biventricular LGE or LGE > 7% of LV mass.
Discussion
Our findings demonstrate that the extent and distribution of myocardial LGE in a cohort of predominantly middle-aged Caucasian women with chronic pulmonary sarcoidosis correlates with ventricular volumes and systolic impairment and Right ventricular scar predicts outcome in sarcoidosis most significantly predicts adverse (arrhythmic) outcome. Our study is the first to prospectively detail RV assessment and include T2-weighted assessment in the majority of patients (Table 1B) .
Recently, systolic RV impairment, multi-focal RV LGE, and active RV granulomatous inflammation in CS were associated with LV LGE, sVT, and death. 2, 7, 11, 12, [16] [17] [18] Our study is the first to demonstrate the direct relationship between RV LGE, RV Figure 5 The implanted implantable cardioverter defibrillator detected episodes of sustained ventricular tachycardia after 18 months. The top strip demonstrates unsuccessful implantable cardioverter defibrillator discharge for fast monomorphic ventricular tachycardia (VT), with eventual ventricular fibrillation (VF) successfully reverted to a paced rhythm. volumes, RV systolic impairment, sVT, and death of all cause. In the absence of data on VT morphology, it remains unclear whether the prognostic relevance of RV LGE is related to more extensive biventricular arrhythmogenic substrate or whether RV LGE itself is particularly arrhythmogenic. 18, 24 None of our patients with asymptomatic LGE suffered adverse cardiac events, while the majority of arrhythmic endpoints (75%) occurred in patients with LVEF > 35%. Our findings support the findings of several recent studies, which evaluated the risk of SCD in CS patients and also recorded appropriate ICD therapy in a large proportion of patients with LVEF > 35%. 4, 7, 12, 22 The risk of VT and SCD in CS seems primarily related to amount and distribution of granulomas and scar and not the systolic function. Arrhythmic substrate imaging with DECMR and/or PET determines the risk of arrhythmic events more accurately than LVEF. 2, 4, 7, 12, 17, 18, 22, 24 The negative predictive value of LGE negative DECMR is excellent, with only one patient with LV LGE < 8% developing an arrhythmic event after 10 months of follow-up. In the absence of prospective data, it seems prudent to follow asymptomatic sarcoidosis patients up with ECG and cardiac ultrasound and evaluate suspected or confirmed CS with PET and/or DECMR. 22 Ongoing research will determine the optimal study follow-up interval. By reserving DECMR for sarcoidosis patients with cardiac symptoms, and/or abnormalities on basic assessment (resting ECG, ambulatory rhythm monitoring, and/or cardiac ultrasound), and implanting ICDs in patients with LGE ≥ 7%, costs could be contained and benefit optimized-in our study, one appropriate shock was delivered for every 2.5 implanted devices. Our appropriate annual ICD therapy/discharge rate of 11.1% compares with the 8.6-14.5% previously reported. 22 The value of routine programmed electrical stimulation as part of risk stratification in patients without palpitations or pre-syncopal events with LGE and LVEF > 35% remains to be determined. 22 Our study supports the recommendations of the 2014 HRS guidelines concerning the use of DECMR and device implantation. 22 The prognostic studies summarized in Table 1B generally report LGE in 25-30% of unselected patients cohorts and uniformly confirm the relationship between the extent of LGE and adverse outcome. Our study confirmed the favourable prognosis of small, asymptomatic myocardial scars as previously reported. 7, 9, [12] [13] [14] The remarkable difference between our conclusions and those of Patel et al., who reported small asymptomatic scar in patients with mildly impaired systolic ventricular functions to be a strong risk factor for adverse events, could partly be explained by a difference in patient population and the distribution of LGE. 4 Patel's cohort mainly consisted of African American women with RV LGE in 67%, a potentially high-risk scenario. Long-term outcomes in patients with CS have markedly improved because of modern heart failure management, including device therapy and arrhythmia ablation in selected patients. 10, 11, 18, 25, 26 Current annual mortality rates range from 0-4.2/100 patients compared with 7.5-12/100 patients as previously reported by Yazaki (2001) and Fleming (1987) . 22 Our study is the first to include data on T2-weighted oedema imaging. Active myocardial inflammation may increase arrhythmogenicity, but conflicting data exist concerning the efficacy of current immune-suppressive and anti-arrhythmic treatment in actually improving longterm outcomes in patients with active disease. 11, 12, 18, 22, [24] [25] [26] The presence of increased T2 signal in our cohort, managed with corticosteroids and methotrexate, did not correlate with adverse events during follow-up. The accuracy for detecting active granulomatous sarcoidosis with T2-weighted spin echo sequences is however suboptimal, and we may well have underestimated inflammatory changes.
3 T2-mapping and fluorodeoxyglucose positron emission tomography (FDG-PET) have shown promise in diagnosing active disease and guiding immune-suppressive management and have replaced spin echo assessment. 2, 12, 18, 27 Study limitations Our study is limited by relatively small number of, predominantly Caucasian, patients and few events. African American and Japanese populations generally have higher rates of cardiac involvement with more extensive myocardial involvement and possibly a more malignant course. 4, 7, 12, 26 Intermittent ambulatory rhythm monitoring may have missed sVT. However, the long-term outcome in our cohort still remained favourable. T1/T2 mapping would have increased the detection of interstitial fibrosis and inflammation and have potentially increased prognostic accuracy.
27,28
Conclusions
The LGE is the strongest, independent CMR predictor of future adverse cardiac events in sarcoidosis patients. RV involvement in addition to LV LGE increases risk of adverse cardiac outcomes and death of all causes. DECMR should ideally be performed in sarcoidosis patients with cardiac symptoms. Asymptomatic patients with LGE < 8% of LV mass and mildly impaired LVEF may not benefit from device therapy and be monitored. Future prospective studies will help determine the timing of DECMR studies. Current medical management including device therapy has improved survival in this condition. 10, 17, 22, 26 Perspectives Biventricular myocardial LGE is the strongest, independent CMR predictor of future adverse cardiac events in sarcoidosis Right ventricular scar predicts outcome in sarcoidosis patients. DECMR should ideally be performed in every sarcoidosis patient with cardiac symptoms and/or abnormal basic assessment. The presence of symptoms and extent of LGE, and not predominantly LVEF, will guide the managing clinician in when to implant an ICD. Asymptomatic Caucasian patients with limited LGE < 8% of LV mass, and preserved LVEF, may not benefit from device therapy and can be safely observed. Future research will focus on comprehensive diagnostic and prognostic strategies, which will include serological markers of disease activity and heart failure, LGE characteristics, and pre-contrast and post-contrast T1/T2 mapping to evaluate interstitial fibrosis and extracellular matrix volume. Hybrid PET-CMR imaging may optimize detection and management of active inflammation. DECMR may help plan VT ablation and potentially increase success rates and outcomes.
